Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data.
Schmid S, Klingbiel D, Aebi S, Goldhirsch A, Mamot C, Munzone E, Nolè F, Oehlschlegel C, Pagani O, Pestalozzi B, Rochlitz C, Thürlimann B, von Moos R, Weder P, Zaman K, Ruhstaller T. Schmid S, et al. Among authors: oehlschlegel c. BMC Cancer. 2019 Sep 10;19(1):902. doi: 10.1186/s12885-019-6105-3. BMC Cancer. 2019. PMID: 31500588 Free PMC article. Clinical Trial.
Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03).
Koeberle D, Ruhstaller T, Jost L, Pagani O, Zaman K, von Moos R, Oehlschlegel C, Crowe S, Pilop C, Thuerlimann B; Swiss Group for Clinical Cancer Research (SAKK). Koeberle D, et al. Among authors: oehlschlegel c. Endocr Relat Cancer. 2011 Mar 9;18(2):257-64. doi: 10.1530/ERC-10-0317. Print 2011 Apr. Endocr Relat Cancer. 2011. PMID: 21317203 Clinical Trial.
Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99.
Pagani O, Klingbiel D, Ruhstaller T, Nolè F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C, Munzone E, Pestalozzi B, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, von Moos R, Zaman K, Goldhirsch A; Swiss Group for Clinical Cancer Research (SAKK). Pagani O, et al. Among authors: oehlschlegel c. Ann Oncol. 2017 Feb 1;28(2):305-312. doi: 10.1093/annonc/mdw622. Ann Oncol. 2017. PMID: 27998961 Free article. Clinical Trial.
Lesions with unclear malignant potential (B3) after minimally invasive breast biopsy: evaluation of vacuum biopsies performed in Switzerland and recommended further management.
Saladin C, Haueisen H, Kampmann G, Oehlschlegel C, Seifert B, Rageth L, Rageth C, Stadlmann S, Kubik-Huch RA; MIBB Group. Saladin C, et al. Among authors: oehlschlegel c. Acta Radiol. 2016 Jul;57(7):815-21. doi: 10.1177/0284185115610931. Epub 2015 Nov 8. Acta Radiol. 2016. PMID: 26552694 Free PMC article.
Ex vivo evaluation of coronary atherosclerotic plaques: characterization with dual-source CT in comparison with histopathology.
Leschka S, Seitun S, Dettmer M, Baumüller S, Stolzmann P, Goetti R, Scheffel H, Feuchtner G, Wunnicke K, Wildermuth S, Oehlschlegel C, Marincek B, Jochum W, Alkadhi H. Leschka S, et al. Among authors: oehlschlegel c. J Cardiovasc Comput Tomogr. 2010 Sep-Oct;4(5):301-8. doi: 10.1016/j.jcct.2010.05.016. Epub 2010 Jun 8. J Cardiovasc Comput Tomogr. 2010. PMID: 20947041
18 results